Abstract: A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.

Abstract: A biopolymer film is provided that comprises a combination of crystalline nano cellulose (CNC)/esterified crystalline nano cellulose (ECNC) reinforced with chitosan. The two polymer components can be present in any ratio, but an approximate CNC to ECNC 70:30 ratio is preferred. The chitosan component is derived from exoskeletons of crustaceans. Also provided are methods of preparing biopolymer film and preparing food packaging components from said biopolymer film. The CNC/ECNC mixture is dissolved in an ethanol solution and the chitin is dissolved in acetic acid and mixed together to form a polymer blend.

Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Abstract: This document provides compositions comprising (or consisting essentially of or consisting of) one or more water-soluble oils selected from the group consisting of ethoxylated macadamia oil, ethoxylated olive oil, ethoxylated avocado oil, ethoxylated meadowfoam oil, ethoxylated almond oil, ethoxylated corn oil, ethoxylated soybean oil, ethoxylated jojoba oil, ethoxylated seabuckthorn oil (e.g., fruit, berry, or seed oil), ethoxylated emu oil, ethoxylated mink oil, PEG Glyceryl Dimyristate, PEG Glyceryl Dioleate, PEG Glyceryl Distearate, and PEG Glyceryl Palmitate; and one or more agricultural chemical or biological agents. Methods for making and using the compositions also are provided.

Abstract: In an example, a method is described that includes generating a model for fabricating an item via an additive manufacturing process. The model includes a first region defining the item and a second region defining a sacrificial artifact whose presence disguises a physical characteristic of the item. The item and the sacrificial artifact are then fabricated in a common build batch via the additive manufacturing process.

Abstract: Oxidase-based sensors and methods of using the sensors are provided.

Abstract: An oral dissolving film containing nano- or micro-encapsulated bioactive material and methods of forming the film. The film may be prepared by dispensing a mixture of a film-forming agent, a crosslinking agent, a solution of nano- or micro-encapsulated bioactive material, and a photoinitiator into a plurality of wells in a tray using a 3D printer. The dispensed material is exposed to radiation in order to crosslink the material and form a film.

Abstract: A composite includes a polymer network including pectin or a pectin derivative; a low-molecular compound having a hydrophilic group in the polymer network; and a polyvalent metal ion coordinated with an anion present in the polymer chain of the polymer network.

Abstract: A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold.

Abstract: Provided are synthesis methods of polymerizing aniline or derivatives thereof. The production of polyaniline or polyaniline derivatives is controlled by the type of oxidant added in the reaction medium. The methods include the step of using a safe and environmentally friendly carbomethyl cellulose (CMC) or modified CMC as an oxidant in the polymerization reaction to produce polyaniline or aniline derivatives. Synthesis methods of producing O-CMC and O-CMC-S oxidants are also provided herein.

Abstract: This invention relates to a curable composition comprising: I. Component (I) comprising at least one resin having at least one functional group selected from the group consisting of ?-ketoester and malonate functional groups, II. Component (II) comprising at least one curing agent having at least one aldehyde functional group, and III. Component (III) comprising at least one compound having amine functionality, salts thereof, or combinations thereof; IV. Component (IV) which is at least one additive comprising at least one adhesion promoter, at least one green strength enhancer, or combinations thereof, or wherein said at least one additive is both an adhesion promoter and a green strength enhancer.

Abstract: The disclosure provides compositions comprising a disaccharide, a nutrient, and a buffer, which may be used for the preservation of bacteria, such as during lyophilization and/or extended storage. Provided herein are methods for preserving bacteria, involving adding bacteria to the compositions and subjecting the compositions to a lyophilization cycle. Also provided herein are methods for generating compositions that may be used, for example for the preservation of bacteria.

Abstract: This invention relates to an assembly component comprising at least one substrate coated with at least one curable composition comprising: I. a first component (I) comprising a resin having at least one functional group selected from the group consisting of ?-ketoester and malonate functional groups, II. a second component (II) comprising at least one curing agent having at least one aldehyde functional group, and III. a third component (III) comprising at least one compound having amine functionality, salts thereof, or combinations thereof.

Abstract: An effervescent developer precursor for preparing a developing solution for developing a lithographic printing plate precursor including an effervescence generating compound.

Abstract: Nitric oxide-releasing mesoporous silica nanoparticles (MSNs) were prepared using an aminosilane-template surfactant ion exchange reaction. Initially, bare silica particles were synthesized under basic conditions in the presence of cetyltrimethylammonium bromide (CTAB). These particles were functionalized with nitric oxide (NO) donor precursors via the addition of aminosilane directly to the particle sol, and a commensurate ion exchange reaction between the cationic aminosilanes and CTAB. N-diazeniumdiolate NO donors were formed at the secondary amines to yield NO-releasing silica MSNs. Tuning of the ion exchange-based MSN modification approach allowed for the preparation of monodisperse particles ranging from 30 to 1100 nm. Regardless of size, the MSNs stored appreciable levels of NO (0.4-1.5 ?mol/mg) with tunable NO-release durations (1-33 h) dependent on the aminosilane modification. The range of MSN sizes and NO release demonstrate the versatility of this strategy.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: A method for producing a purified cannabis extract includes providing a first extract with an organic hydrophilic solvent, at least one cannabinoid, and water at concentration W1 by weight, and at least one impurity at impurity to cannabinoid weight/weight ratio R1; adding water to the first extract to reach water concentration W2 by weight, whereby a solid matter and a second extract are formed; separating the solid matter from the second extract, whereby separated solid matter and separated second extract are formed. The separated second extract includes the organic hydrophilic solvent, the at least one cannabinoid, and water to cannabinoid weight/weight ratio R2.

Abstract: A method for providing a solution of a substance in a microfluidic device includes providing a dispersion of a first medium and of a lyophilizate of the substance, the lyophilizate being insoluble in the first medium, and adding a second medium to the dispersion, the lyophilizate being soluble in the second medium. The method further includes dissolving the lyophilizate in the second medium such that the solution of the substance in the second medium is obtained, and separating the solution obtained by the dissolving of the lyophilizate from the first medium.

Abstract: An injectable hydrogel composition that forms a porous gel rapidly after injection fro tissue engineering. The composition comprises a biodegradable, biocompatible, gelling polymer, that is optionally reverse-gelling; an Extra cellular matrix (ECM) material and a biocompatible porogen. Methods of making and using the composition are provided. A kit also is provided comprising the ingredients for making the hydrogel.

Abstract: Described herein are molded dehydrated placental tissue compositions, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the molded dehydrated placental tissue compositions are also described herein.

Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.

Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.

Abstract: In one aspect, the disclosure provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit cell binding specificity. For example, MSNPs and protocells of the disclosure may be used to target specific delivery of therapeutic agents to CD19 or EGFR expressing cancer cells, or target specific delivery of therapeutic agents to other cell types. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract: The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses.

Abstract: The disclosure provides implants containing a plurality of particles containing at least one population of viable cells adherent to and resident in soft tissue matrix or at least one viable population of cells caused to be in contact with the soft tissue matrix; methods of fabricating the implants; and use of the implants in tissue repair.

Abstract: Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

Abstract: Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia.

Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.

Abstract: This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

Abstract: The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.

Abstract: Compositions and methods for sealing tissue of a patient in a wet environment are disclosed.

Abstract: The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

Abstract: A method for rapid antibiotic susceptibility testing by tracking sub-micron scale motion of single bacterial cells including obtaining a biological sample from a subject including live bacteria. Different doses of antibiotic are added to a multi-well glass slide and adding portions of the biological sample to the wells. Bacterial cells are tethered onto the surface. The tethered bacterial cells are imaged and tracked. Bacterial sub-micron motion of tethered cells is measured at the different doses. A processor performs statistical analysis on a population of cells for each antibiotic dose to generate an antibiotic dose curve proportional to the motion changes, where the antibiotic dose curve plots data including a decrease in movement over time indicating a proportional effectiveness of an antibiotic applied to a well.

Abstract: Various embodiments disclosed herein include methods of modulating the function of Zinc Activated Cation Channel (ZACN) in a subject comprising: administering to the subject a pharmaceutically effective dosage of ATP, a purinergic compound, red or blue dye, heparin or heparin analog, desipramine, reboxetine, and/or tomoxetine; and modulating the function of ZACN in the subject. Various embodiments disclosed herein also include methods of treating a disease in a subject comprising: administering to the subject a pharmaceutically effective dosage of a compound capable of modulating the function of the Zinc Activated Cation Channel (ZACN), and treating the disease.

Abstract: Disclosed herein is zinc/amino acid functionalized silica, compositions comprising the same, and oral care methods and uses for such compositions.

Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.

Abstract: The disclosure provides biomaterials including scaffolds that include blood products including blood fractions and products including platelets for administration to subjects in need thereof. More specifically, the scaffolds based on step growth polymers are enriched with blood extracts that contain platelet rich plasma (PRP) and/or extracts of platelets. Compositions comprising a biomaterial or precursor thereof and a blood extract are provided, as are methods of making and using the biopolymers or precursors thereof. Kits and articles of manufacture comprising the biopolymers or precursors thereof are also described.

Abstract: The present disclosure provides veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The disclosure also provides methods of treating trichomoniasis in a bovine and methods of treating a Tritrichomonas foetus infection in a bovine utilizing the veterinary formulations.

Abstract: The present disclosure provides compositions comprising Ganoderma immunomodulatory protein or a recombinant thereof and a gel-forming agent. Also provided are methods for the treatment of chronic wounds, ulcers or sores, and methods using the compositions.

Abstract: Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.

Abstract: The present invention relates to liquid fabric softener compositions comprising a quaternary ammonium ester softening active, cellulose fibers, and benefit agent capsules comprising a core and a shell encapsulating said core, wherein said shell comprises polyacrylate polymer, as well as methods of treating fabric and using same. Such liquid fabric softener compositions provide similar deposition of different types of fabric material.

Abstract: Provided are methods for producing mesoporous nanoparticles that can, once loaded, retain small or large molecules (e.g., molecules having a molecular weight that is less or greater than about 900 Da) until release is desired, upon which time the mesoporous nanoparticles can release the loaded molecule in a controlled manner for a desired period of time, including an extended period of time. Also disclosed are methods for treating a subject comprising administering to the subject a mesoporous nanoparticle according to the present disclosure.

Abstract: An adhesive composition that exhibits excellent adhesive performance such as curved surface adhesiveness to low-polarity adherends and constant load peeling properties in high-temperature environments, and also an adhesive sheet and a method for producing the same.

Abstract: A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

Abstract: Provided herein are compositions and kits including a pathogen-inactivated cryoprecipitate suitable for infusion into a subject at least 1 day after thawing. The methods are useful in the efficient preparation of cryoprecipitates with desirable characteristics, including pathogen-inactivated cryoprecipitates that are suitable for infusion into a subject at least 1 day after thawing.

Abstract: The present invention relates to an oral film consisting essentially of dexamethasone and hydroxypropyl methylcellulose, wherein the concentration of dexamethasone is 30% w/w or more and the concentration of hydroxypropyl methylcellulose is between 35 and 70% w/w based on total dry matter.

Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.

Abstract: Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.

Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.

Abstract: Fertilizers with urease inhibitors and/or nitrification inhibitors are described. The fertilizer can include an extruded granule containing urea, a polymeric binder, and a nitrification inhibitor and/or an urease inhibitor.